Ming-Fu (Alan) Chiang

Director at NeOnc Technologies

Capital raised by NeOnc Technologies

$27.3M+$5.0M latest round

4 Form D filings · first filed Mar 2025 · Westlake Village, CA

CURRENT ROLE: Director
SECTOR: Biotech
COMPANY FILINGS: 4
TEAM ON FILE: 5
FOUNDED: 2023
30D INTEREST: 1 ↗

Career

1 company on file · founded 2023

NeOnc TechnologiesBiotech · Westlake Village, CAsince 2023

Director

Listed on NeOnc Technologies's Form D filings

Company filings

via EDGAR · Form D for NeOnc Technologies4

DateCompanyFormAmountRole on filing

Jun 10, 2026NeOnc TechnologiesForm D+$5.0M—

Form DJun 10, 2026 · NeOnc Technologies+$5.0Mnot a signer

Jan 29, 2026NeOnc TechnologiesForm D+$10.6M—

Form DJan 29, 2026 · NeOnc Technologies+$10.6Mnot a signer

Mar 26, 2025NeOnc TechnologiesForm D+$1.6M—

Form DMar 26, 2025 · NeOnc Technologies+$1.6Mnot a signer

Mar 10, 2025NeOnc TechnologiesForm D+$10.0M—

Form DMar 10, 2025 · NeOnc Technologies+$10.0Mnot a signer

Overview

Last filing Jun 10, 2026

Ming-Fu (Alan) Chiang is on file as Director at NeOnc Technologies in Westlake Village, CA. NeOnc Technologies has 4 Form D filings on record, $27.3M raised in total.

Teammates

NeOnc Technologies · 4

Amir HeshmatpourChief Executive OfficerSigner Amir HeshmatpourDirector Jim DelshadDirector Thomas C. ChenChief Executive OfficerSigner

Products

NeOnc Technologies · 1

NEO100CNS Therapeutics

NEO100 is a highly purified form of perillyl alcohol (POH) that is administered intranasally. It is currently undergoing Phase II clinical trials specifically targeting patients with recurrent malignant glioma and malignant skull-based meningioma, aiming to provide an innovative solution in the treatment of these challenging CNS tumors.